Steven Rosenzweig, Ph.D.
Drug delivery of small and large molecules to difficult to access tumors
Research Interest
As Associate Director of Shared Resources since 2007 at the Medical University of South Carolina (MUSC) Hollings Cancer Center (HCC), I work with each shared resource director with the singular goal of providing state of the art services and the latest cutting-edge instrumentation for each facility to support the cancer research activities of center members. The focus of my lab is on the dysregulation of growth factor signaling in cancer. Work on the IGF system in head and neck squamous cell carcinoma progression, invasion, and therapeutics. A thread through these studies is development of IGF inhibitors based on IGFBP2. These analyses led to the discovery that the C-terminal 41 residues of IGFBP2 can spontaneously form nanotubes (NTs). A patent was submitted (#20200206313) and Somatoceutics, LLC was launched in South Carolina to commercialize SMC-101 NTs as therapeutic drug delivery agents.